SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights

... net loss per share was 61,137,755 for this period versus 47,146,856 for the second quarter of 2008. ... the first six months of 2009 were $55.9 million, versus $41.2 million for the comparable period in 2008. ... loss per share was 61,078,534 for this period versus 46,238,618 for the first half of 2008. ...

Sanofi-aventis Announces Second Quarter 2009 Results

... the first half of 2009 was euro 2,637 million, versus euro 2,335 million for the first half of 2008. ... the results of a 5-year study of Lantus ((R)) versus NPH insulin on progression of retinopathy in ... and general expenses to net sales was 24.9% versus 26.2% for the first half of 2008, thanks to the ...

NeoGenomics Reports Second Quarter 2009 Results

... Highlights: Revenue increased 53% versus Q2 08 to $7.5 million Revenue increased ... performed. Average revenue per test was flat versus last quarter. Gross profit margin remained ... controlled and decreased by 5% or $126,000 versus Q1 09. Total SG&A expenses as a percentage ...

Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa

... percent in the corifollitropin alfa treatment arm versus 1.6 percent in the rFSH treatment group.(5) ... the corifollitropin alfa group was 13.3 (+/-7.3) versus 10.6 (+/-5.9) in the reference group.(5) ... Behr B, et al Corifollitropin alfa versus recombinant FSH treatment in controlled ovarian ...

Phase 3 Cystic Fibrosis Trial Results Presented at European Conference

... for the 26 weeks was lower for Bronchitol versus control: overall reduction in rate of 25% ... compared with placebo, included cough (25.4% versus 20.3%), haemoptysis (11.9% versus 8.5%) and pharyngolaryngeal pain ...

Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions

... experienced by patients treated with Contrave versus placebo (p< 0.01), as well as previously ... or 9.3% to 11.5% of their baseline body weight, versus 11.0 pounds to 16.0 pounds, or 5.1% to 7.3% of ... in NB-302 was 25.9% for patients taking Contrave versus 13.0% for those taking placebo. The most ...

Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

... liposomal doxorubicin (PLD) plus bortezomib (B) versus B alone in previously treated multiple myeloma ... (T) with pegylated liposomal doxorubicin (PLD) versus PLD alone (Abstract 5550) ... with pegylated liposomal doxorubicin (PLD) versus PLD alone (Abstract 5526) Poster ...

Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial

... was 2.3 percent in patients taking prasugrel versus 3.1 percent in patients taking clopidogrel ... attack, or stroke by 19 percent (9.9 percent versus 12.1 percent), with an increased risk of major ... 4) Wiviott, S, Braunwald, E, et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary ...

Lilly Set to Unveil More Than 50 Studies at ASCO 2009

... pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III ... analysis of a phase III study comparing PC versus gemcitabine-cisplatin (GC) in first-line ... + carboplatin (Cb) plus or minus enzastaurin (E) versus docetaxel (D) + Cb as first-line treatment of ...

Beckman Coulter Announces First Quarter 2009 Results

... the greatest decline, off more than $18 million versus an unusually strong first quarter 2008 when a ... cash instrument sales were off nearly 20%, versus a strong prior year quarter in which cash ... gross margin increased 100 basis points to 46.1% versus first quarter 2008 due to favorable product mix. ...

Thoratec Announces Filing of PMA Seeking Destination Therapy Approval for HeartMate II(R)

... superiority in favor of the HeartMate II versus the control group. As a result, Thoratec and the ... II achieved statistically superior outcomes versus those in the control group who were implanted ... were significantly lower for the HeartMate II versus the XVE. As a result, this submission seeking ...

Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session

... measured by the SPECT total severity score, (-256 versus +13, p=0.01). Further, patients receiving 10 or ... out of a ventricle with each heartbeat, (+4% versus +1%); end systolic volume (-5.7mL versus -0.1mL); and infarct size, tissue death due to ...

WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results

... Dr. Li concluded. Total Company - versus Guidance Total company(1) full-year 2008 ... fourth-quarter and full-year 2008, respectively, versus 43% and 46% for fourth-quarter and full-year ... net income increased 56% and 31%, respectively, versus 87% growth in revenue. The lower rates of growth ...

Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008

... in revenue for the fourth quarter of 2008 versus the fourth quarter of 2007, and a 72% increase in revenue for the year ended December 31, 2008 versus 2007. Fourth quarter 2008 revenue from ... revenue growth. Revenue in 2008 was $73.7 million versus $43.0 million in 2007. Case volume in the ...

OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009

... rates for Avastin plus chemotherapy versus chemotherapy alone were reported as 51% versus 44%, respectively, at one year and 23% versus 15%, respectively, at two years. - ...

Gentiva Reports Fourth Quarter and Fiscal 2008 Results

... improved to 10.6% in the fourth quarter of 2008 versus 8.1% in the prior-year period. ... Net revenues of $1.30 billion versus $1.23 billion in the prior year. Net revenues in ... An EBITDA increase of 14% to $114.1 million versus $99.7 million in the prior-year period. ...

OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer

... Survival rates for Avastin plus chemotherapy versus chemotherapy alone were reported as 51% versus 44% at one year and 23% versus 15% at two years, respectively. "The two-year ...

Uroplasty Reports Third Quarter Fiscal 2009 Results

... third quarter of fiscal 2009 were $3.4 million versus $3.7 million during last fiscal year's third ... patient group, the dry/cure rate was 36.9% versus 24.8% in the control patient group. The authors ... 31, 2008 was $894,000, or $0.06 per diluted share versus $900,000, or $0.06 per diluted share for the ...

Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy

... seizure reduction and improved seizure freedom versus placebo when added to first and second-generation ... Budapest. "Vimpat(R) showed significant efficacy versus placebo in a challenging clinical trial patient ... seizure frequency per 28 days from baseline versus placebo (20.5 percent for placebo, 35.3 percent ...

Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55

... expense and certain other expenses, were $4.55 versus $4.29 in 2007, a 6 percent increase. Full year ... and certain other expenses, was $4,885 million versus $4,804 million in 2007, a 2 percent increase. ... Full year 2008 GAAP net income was $4,196 million versus $3,166 million in 2007. GAAP reported results ...

Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints

... or 9.3% to 11.5% of their baseline body weight, versus 11.0 pounds to 16.0 pounds, or 5.1% to 7.3% of ... pounds, or 8.1% of their baseline body weight, versus 10.6 pounds, or 4.9% of baseline body weight for ... events was 25.9% for patients taking Contrave versus 13.0% for those taking placebo. The ...

Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery

... efficacy endpoint of reducing post-surgical pain versus placebo (p=0.03) following total knee ... an advantage in pain management for Adlea versus placebo, with a similar safety profile. ... 48 hours post-surgery for Adlea-treated patients versus placebo, although the primary endpoint, pain at 4 ...

Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting

... Vimpat(R) provides consistent seizure reduction versus placebo, when added to concomitant AEDs, and that ... in seizure frequency was observed versus placebo (34.0 percent Vimpat(R) group vs. 20.0 ... group demonstrated significant seizure reduction versus placebo in the phase III trial (SP 755), but not ...

New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohn's Patients With Fistulizing Disease

... (73.3%) maintained 50% fistula closure at Week 26 versus patients receiving placebo (38.5%). More than ... a higher percentage of patients in the CIMZIA(R) versus placebo group achieved CDAI response of 100 points from baseline (71.4% versus 33.3%, respectively) and CDAI remission ...

Tianyin Pharmaceutical Co., Inc. Announces First Quarter 2009 Financial Results

... in the three months ended September 30, 2008, versus $27,451. Operating income for the first quarter ... $35.1 million, with total assets of $38.5 million versus total liabilities of $3.4 million. For the first ... generated $0.5 million in cash from operations versus $1 million for the same period in 2008. ...

American Oriental Bioengineering Reports Third Quarter 2008 Financial Results

... $16.5 Million -- -- 3Q08 Diluted EPS $0.21 versus 3Q07 Diluted EPS $0.16 -- NEW YORK, Nov. 10 ... percentage of total revenue to approximately 12% versus 18% in the comparable period. The increase ... We are also extremely well-capitalized versus competitors, with over $220 million of cash ...

ev3 Inc. Reports Third Quarter 2008 Financial Results

... increased 21% in the third quarter of 2008 versus the prior year quarter. By product segment, third ... share was $(0.07) for the third quarter of 2008 versus a net loss per common share of $(0.60) in the ... quarter of 2008 increased 73% to $66.9 million versus $38.7 million in the third quarter of 2007. On a ...

Thoratec Reports 44 Percent Increase in Third Quarter Revenues

... of $16.2 million, or $0.28 per diluted share, versus a net loss of $430,000, or $0.01 per share, in ... in revenues from our Cardiovascular Division versus a year ago," said Gary F. Burbach, president and ... Division revenues were $57.1 million versus $34.0 million in the same period a year ago. ...

Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal 2009

... weight of increased sales of distributed products versus the sales of manufactured products, which had an ... which earn lower margins as a percentage of sales versus the sale of other distributed products. Net sales ... determine the mix of distributed product sales versus manufactured product sales in any given period as ...

Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23

... the third quarter of 2008 to $3,875 million versus $3,611 million in the third quarter of 2007. ... totaled $2,929 million, an increase of 4 percent versus $2,809 million in the third quarter of 2007. ... sales increased 20 percent to $855 million versus $715 million for the third quarter of ...

Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months

... (7% excluding the impact of foreign exchange) versus the 2007 third quarter, primarily due to the ... items, decreased 1% for the 2008 third quarter versus the 2007 third quarter. Other (income) expense, ... in the tax rate for the 2008 third quarter versus the 2007 third quarter resulted primarily from ...

Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes

... both groups (endpoint A1C: 7.1 plus or minus -0.7 versus 7.0 plus or minus 0.7%; both p<0.0001 versus LANTUS(R) alone) with 50.6% and 54.6% of ... in weight changes (+0.4 plus or minus 3.0 versus +0.1 plus or minus 5.0 kg) in LANTUS(R) (29 plus ...

Essilor's First-Half 2008 Results

... and accounted for 38.9% of consolidated revenue, versus 39.8% in the prior-year period, when they ... expenses of EUR190.3 million (12.5% of revenue versus 13.0% in first-half 2007). The Company ... Transitions-which amounted to EUR14.7 million, versus EUR15.3 million in first-half 2007. Earnings ...

Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery

... setting) in patients treated with Gleevec versus placebo(2). In early 2007, the study met its ... Study of Adjuvant STI571 (Gleevec(R)) versus Placebo in Patients Following the Resection of ... of Oral Cancer Therapy for Medicare Beneficiaries versus Currently Covered Therapy, Part 2. Imatinib for ...

CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results

... the quarter ended June 30, 2008 was $2,176,679 versus a loss of $3,776,263 during the same quarter in ... nine months ended June 30, 2008 was $7,129,215 versus a loss of $7,368,779 during the same nine months ... for the quarter ended June 30, 2008 was $0.02 versus a net loss per common share of $0.05 during the ...

China Bio Energy Holdings Group Reports Second Quarter 2008 Financial Results

... gross profit increased to $13.6 million, or 360%, versus $3.0 million in the prior year period. ... Net income increased 484% to $8.3 million versus $1.4 million in the prior year period. Net margin ... per month. Bio-diesel revenue more than doubled versus the first quarter of this year as we were able to ...

Is GMO Food and Organic Food an Either/Or Proposition?

... Benefits of GMO Foods versus Organic Food featured in Conversations about ... [benefits of GMO foods versus organic food] is a humorous and entertaining look ... [benefits of GMO foods versus organic food video] - can be viewed, downloaded ...

Gentiva Reports Strong Second Quarter led by Home Health Segment

... A 13% increase in net revenues to $346.2 million versus the second quarter ended July 1, 2007. -- A 34% ... to $12.0 million, or $0.41 per diluted share, versus $9.0 million, or $0.31 per diluted share, for the ... Average diluted shares were 29.2 million versus 28.5 million in the second quarter of 2007. -- ...

Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009

... weight of increased sales of distributed products versus the sales of manufactured products, which had an ... of increased sales of Paragraph IV products versus the sales of other distributed products. Products ... determine the weight of distributed product sales versus manufactured product sales in any given period, ...

Beckman Coulter Announces Second Quarter 2008 Results

... profit margin improved 30 basis points to 46.2% versus second quarter 2007. Operating income was $74 ... Non-operating expense was $8.7 million versus non-operating income of $29.8 million in the ... growth was 12.8% in constant currency, versus first half 2007. Year-to-date recurring revenue ...